SOX9 and Duchenne muscular dystrophy: In conclusion, our data support the overall safety and therapeutic efficacy in GRMD dogs of both LR and systemic transvenous infusion of rAAV2/8-Spc512-cMD1, paving the way for human clinical trials for either upper limb or whole body delivery in a manner potentially therapeutic for any DMD patients irrespective of their mutation genotype.